Congestive heart failure is a serious condition facing people around the world. Early trials of a gene therapy have showed promise to not only help these patients with the condition but also make their hearts healthier.
Jack W. Reich, PhD, CEO of Renova Therapeutics discussed the results of a phase II study during the European Society of Cardiology's annual conference in London.
Patients with congestive often need treatment for a long time to manage their condition. A new option being tested could fix the problem in a shorter period of time and provide a better quality of life.
The phase II trials of a gene therapy showed good results but it will likely be a while before it becomes a regular treatment option in the field. What that will mean for congestive heart failure and other conditions remains to be seen.